Kingston Health Sciences Centre (KHSC) is celebrating the completion of the region’s first positron emission ...
CytoSite Bio (CytoSite) announced today that they have signed a collaboration agreement for the clinical development and potential commercialization of CytoSite's investigational Phase 1 ready ...
Huron Daily Tribune on MSN15h
Bad Axe business owner sees major progress in cancer battleThe victory totals are starting to swing one local business owner's way as he has positive results in an ongoing battle with lung and brain cancer. Shawn Roehrig, owner of Roland’s Paint and More ...
• In advanced-stage HL, reduction of chemotherapy or radiotherapy after a negative interim PET scan is probably beneficial for overall survival. • Treatment escalation with rituximab after a positive ...
The Kingdom of Jordan recently opened its first advanced nuclear medicine diagnostic centre in a public hospital with IAEA support, significantly increasing access to diagnostic services for cancer ...
Cancer patients across Kenya have been left stranded for over a month, as a crippling shortage of a crucial radiotracer has brought vital diagnostic scans to a halt, delaying detection, treatment, and ...
According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.
Mobile Health Group and Mercy Radiology partnered together in 2024 to roll out Mobile Imaging – New Zealand’s first state-of-the-art mobile PET-CT unit, designed to travel across regions, ensuring ...
The U.S. FDA’s approval of Telix Pharmaceuticals Ltd.’s kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer widens the opportunities for patients who live far away ...
The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.
TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...
Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback